| Literature DB >> 35434355 |
Joseph Ali1,2, Alison F Davis3, Diana J Burgess4,5, Daniel I Rhon6, Robert Vining7, Stacey Young-McCaughan8,9, Sean Green3, Robert D Kerns10,11.
Abstract
Introduction: Pragmatic clinical trials (PCTs) can overcome implementation challenges for bringing evidence-based therapies to people living with pain and co-occurring conditions, providing actionable information for patients, providers, health systems, and policy makers. All studies, including those conducted within health systems that have a history of advancing equitable care, should make efforts to address justice and equity.Entities:
Keywords: equity; ethics; justice; pain management; pragmatic clinical trial
Year: 2021 PMID: 35434355 PMCID: PMC9006531 DOI: 10.1002/lrh2.10291
Source DB: PubMed Journal: Learn Health Syst ISSN: 2379-6146
Justice and equity‐enhancing strategies for PCTs testing nonpharmacological treatments for chronic pain
| Focal area | Examples of challenges | Examples of mitigation strategies |
|---|---|---|
| Study context and design |
Potential for biases, prejudices, and inequities to transfer from health systems to PCTs. |
Understand, prospectively, community attitudes and beliefs regarding a health system and how these might transfer to aspects of trial implementation. Develop, share, and enforce standards for equity and inclusion across the study team and supporting personnel. Develop and employ innovative tools to prioritize equity on a routine basis across a health system (eg, electronic reminders about common health inequities that affect medical treatment). |
|
Limited accessibility to NPTs for some patients due to institutional biases and disincentives against NPTs. Funding system that prioritizes health systems with strong academic partnerships, leading to the underrepresentation of less resourced health systems. |
Engage with institutional leadership prospectively to identify pathways for integration of pragmatism and NPTs. Systematically review portfolios and funding strategies with an eye toward health system diversity, including bias education. Specify and weight criteria that will be applied during grant review processes to achieve more equitable distribution of resources. Incentivize partnerships between less‐resourced health systems with academic research centers. | |
|
Use of study outcome measures that do not necessarily align with what patients are most interested in, and sociodemographic categories that diverge from how participants view themselves. |
Engage patients/other stakeholders to identify meaningful study outcomes among specific populations. If needed, supplement existing sociodemographic data with current patient‐reported race/ethnicity/ability measures. Create and include patient engagement groups as part of the research team and invite comments on choice and relevance of study outcomes. | |
|
Limits on data collection and trial participation due to reliance on digital systems. |
Provide access to technology, through pragmatic means if feasible (eg, leverage existing technology support programs in healthcare systems). Consider non‐EHR based data collection for some populations | |
| Participant recruitment and retention |
Limited participation of some individuals and groups due to diversity‐insensitive recruitment approaches and materials. |
Identify potential barriers to trial participation prospectively, including through patient questionnaires designed for this purpose. Create and include patient engagement groups as part of the research team who can review and offer feedback on recruitment methods and materials. Include within recruitment materials culturally sensitive and specific images and language that include populations experiencing lower access to care or other known disparities within the study's health system. |
|
Limited participation of some individuals and groups by virtue of their transiency or difficulty accessing well‐established health systems. |
Tailor recruitment to potentially excluded populations (eg, settings known to care for individuals who are transient or who commonly experience health disparities). | |
| Study interventions |
Inflexible interventions that do not align with contextual needs or strong preference of patient populations. |
Identify multiple strategies (eg, individual and group‐delivered interventions; condensed treatment schedules; multi‐lingual therapy) to facilitate intervention delivery for different types of patient populations. |
| Stakeholder engagement |
Limited racial, ethnic, and ability diversity among providers, investigators, and study staff. Inability to identify and respond to individual and structural barriers to trial participation by marginalized populations. |
Engage with diverse patient groups who can review and offer feedback on study design and implementation choices. Invite patients who represent a study population formally to be members of the research team. Offer structural competency and cultural sensitivity training for research and healthcare staff involved in PCTs. Use known strategies to engage investigators from underrepresented groups (eg, diversity supplements; engage institutions that serve minority populations). Encourage sharing of diverse perspectives within teams and actively counter microaggressions, rudeness, and harassment. |
Abbreviations: EHR, electronic health record; NPT, non‐pharmacological treatment; PCT, pragmatic clinical trial.